Caris Life Sciences Q3 net income drops 37% to $15.25 million; Q3 revenue rises 27% to $275.36 million

PUBT · 14h ago
Caris Life Sciences Q3 net income drops 37% to $15.25 million; Q3 revenue rises 27% to $275.36 million
  • Caris Life Sciences' third-quarter 2026 net income fell 37% to $15.25 million, while revenue rose 27% to $275.4 million.
  • Operating cash flow swung to an outflow of $22.2 million, due to commercial expansion, inventory buildup and research investment.
  • Clinical cases climbed approximately 21% year over year to approximately 61,500.
  • Caris Assure launched treatment-response monitoring, while the Caris Confirm minimal residual disease assay remains targeted for launch before year-end.
  • Full-year 2026 revenue guidance increased to $1.04 billion–$1.05 billion, representing growth of 28%–29%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA88569) on November 04, 2026, and is solely responsible for the information contained therein.